

## Index

- A1C
- age in diagnosis, S14
  - CGM effects on, S39, S40, S101
  - in children, S18, S41
  - in children, adolescents, S87
  - CVD outcomes and, S42–S43
  - diagnostic criteria, S13–S14
  - epidemiology, S7
  - goals, S41
  - hyperglycemia and, S9–S10
  - limitations, S41
  - mean glucose levels for specified A1C level, S41
  - microvascular complications, S42
  - older adults, S83
  - pregnancy levels, S95
  - race/ethnicity differences, S14, S41
  - recommendations, S40, S41
  - testing, S40–S41
- acarbose, S55
- access to health care, S8–S9
- ACCORD trial, S10, S31–S32, S42–S44, S61, S62
- ACE inhibitors, S61–S63, S68, S72–S74, S89, S97
- ADAG study, S41, S44
- adherence, S8
- ADVANCE trial, S42–S44, S61
- advocacy, S6, S105–S106
- African Americans, S14, S15, S27
- AIM-HIGH trial, S65–S66
- albiglutide, S50, S53, S54, S56, S58
- albuminuria, S29, S72–S74, S90
- alcohol, S26, S65
- alogliptin, S53–S55, S68
- amlodipine, S63
- amputation, S78
- amylin mimetics, S53, S56
- anemia, S14
- angiotensin receptor blockers, S61, S62, S68, S72–S74, S89, S97
- antidepressants, S49
- antihyperglycemic agents, S100–S101
- antihypertensive agents, S63, S97
- antiplatelet agents, S4–S5, S66–S67, S75
- antipsychotics, S49
- antiretroviral agents, S10
- Antithrombotic Trialists' (ATT) metanalysis, S66
- antivascular endothelial growth factor, S75, S76
- Asian Americans, S8, S15, S17, S47
- ASPIRE trial, S40
- aspirin resistance, S67
- aspirin therapy, S4–S5, S66–S67, S75
- atherosclerotic cardiovascular disease. *see* cardiovascular disease
- atorvastatin, S64
- autonomic neuropathy, S29, S76–S78
- $\alpha$ -glucosidase inhibitors, S37, S55
- bariatric surgery, S49–S51, S58
- $\beta$ -blockers, S74
- Belviq (lorcaserin), S50
- benazepril, S63
- bile acid sequestrants, S55
- bipolar disorder, S10
- blood glucose control. *see* glycemic control
- blood pressure control, S60–S63, S81, S88–S89
- body mass index (BMI), S17
- bromocriptine, S55
- calcium channel blockers, S74
- canagliflozin, S53, S54, S56, S58
- cancer, S31
- capsaicin, S77
- carbamazepine, S77
- carbohydrates, S27, S37
- cardiac autonomic neuropathy, S77
- cardiac testing, S67
- cardiovascular disease
- antiplatelet agents, S4–S5, S66–S67, S75
  - in children, adolescents, S88–S89
  - heart failure, S68
  - hypertension/blood pressure control, S60–S63, S81, S88–S89
  - insulin regimens, S43
  - LDL cholesterol, S64, S65, S68
  - lifestyle modification, S7, S36–S37, S47, S48, S62–S64, S68
  - lipid management, S63–S66
  - outcomes, S42–S43, S73
  - overview, S4, S60
  - pharmacological interventions, S62–S63
  - prevention, S26, S27, S37
  - risk calculator tool, S64
  - as risk factor, S16, S60
  - risk factors for, S15, S17, S29, S31, S60, S64, S74
  - smoking and, S29, S89
- care improvement strategies
- adherence, S8
  - advocacy, S6, S105–S106
  - Chronic Care Model, S7
  - delivery systems, S7
  - demographics, S6
  - institutional changes, S7–S8
  - intermediate outcomes, S8
  - objectives, S7–S8
  - outcomes, S8
  - patient-centered, S6
  - processes of care, S8
  - recommendations, S6, S9, S10
  - team building, S7
  - treatment intensification, S8
- child care, school, S86–S87, S105
- children, adolescents
- A1C levels in, S18, S41
  - autoimmune diseases in, S87–S88
  - celiac disease in, S88
  - diabetes management, S87
  - DSME, DSMS, S7, S8–S9, S24–S25, S36, S37, S86
  - dyslipidemia management, S89
  - exercise for, S28
  - glycemic control, S87, S89
  - hypertension, S88–S89
  - hypoglycemia in, S44, S87
  - nephropathy, S27, S29, S72–S74, S89–S90
  - neuropathy, S28–S29, S76–S78, S90
  - pediatric to adult care transition, S91
  - psychosocial issues, S87
  - retinopathy, S28, S73–S76, S90
  - school, child care, S86–S87, S105
  - screening, S87
  - smoking in, S29, S89
  - statins in, S89
  - thyroid disease in, S88
  - type 1 diabetes in, S86–S90
  - type 2 diabetes in, S90–S91
  - vaccination schedule, S29
- chlorthalidone, S63
- Chronic Care Model, S7, S23
- chronic kidney disease, S27, S72–S74
- Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, S73
- classification, S13
- clinical evaluation, S23, S24
- clopidogrel, S66
- clozapine, S49
- cognitive dysfunction, S9–S10, S26, S31–S32, S44, S82
- cognitive function, statin use and, S66
- colesevelam, S55
- complications
- A1C, microvascular, S42
  - epidemiology, S8
  - prevention of, S7, S27
  - risk factors, S14, S29
- consensus reports, S1
- continuous glucose monitoring (CGM), S39, S40, S101
- Contrave (naltrexone/bupropion), S50
- coronary artery calcium screening, S67–S68
- coronary heart disease, S8, S67–S68
- correctional facilities, S106
- cultural differences, S8
- cystic fibrosis, S18
- cystic fibrosis–related diabetes, S20
- dapagliflozin, S53, S54, S56, S58
- dementia, S9, S31–S32, S82
- depression, S10, S30
- Diabetes Control and Complications Trial (DCCT), S42, S44, S52, S87
- diabetes distress, S30
- Diabetes Prevention Program (DPP), S36, S37
- Diabetes Prevention Program Outcomes Study (DPPOS), S36
- Diabetes Prevention Recognition Program (DPRP), S37
- diabetes self-management education, support (DSME, DSMS), S7, S8–S9, S24–S25, S36, S37, S86, S102
- diabetic ketoacidosis (DKA), S13, S16–S17, S45, S58, S90, S101
- diabetic kidney disease, S27, S29, S72–S74
- Diabetic Retinopathy Study, S76
- diagnosis
- A1C (*see* A1C)
  - anemia, S14
  - community screening, S17–S18
  - comorbidities, S31–S32
  - confirmation of, S14
  - fasting test, S13, S14
  - hemoglobinopathies, S14
  - monogenic syndromes, S19–S20
  - one-step strategy, S18–S20
  - plasma glucose criteria, S13
  - prediabetes, S14–S17, S36
  - red blood cell turnover, S14

- referrals, S30  
 2-hour plasma glucose, S13, S14  
 two-step strategy, S19, S20  
 type 1 diabetes (*see* type 1 diabetes)  
 type 2 diabetes (*see* type 2 diabetes)
- diastolic blood pressure, S62  
 diuretics, S61–S63, S74, S97  
 dopamine-2 agonists, S55  
 DPP-4 inhibitors, S53–S55, S58, S68, S101  
 driving, S105  
 dulaglutide, S50, S53, S54, S56, S58  
 duloxetine, S77  
 dyslipidemia, S65, S83, S89
- Early Treatment Diabetic Retinopathy Study, S76  
 eating patterns, S26  
 e-cigarettes, S29  
 empagliflozin, S53, S54, S56, S58, S68  
 EMPA-REG OUTCOME study, S56, S68  
 employment, S105–S106  
 end-of-life treatment, S82–S85  
 energy balance, S26  
 erectile dysfunction, S77–S78  
 ethnic differences, S8, S14, S17, S41  
 euthyroid sick syndrome, S88  
 evaluation, S23, S24, S31  
 EXAMINE trial, S68  
 exenatide, S50, S53, S54, S56, S58  
 exercise, S27–S29, S37, S48  
 ezetimibe, S64, S65
- fasting test, S13, S14  
 fats, S26, S27. *see also* lipid management  
 fatty liver disease, S31  
 fibrate/statin therapy, S65  
 5-HT<sub>2c</sub> receptor agonists, S50  
 fluvastatin, S64  
 food insecurity, S9  
 foot care, S78–S79  
 foundations of care, S23  
 fractures, S31
- gabapentin, S77  
 gastrointestinal neuropathies, S77  
 gastroparesis, S77  
 genitourinary neuropathies, S77  
 gestational diabetes mellitus, S18–S20, S37, S94–S97  
 glibenclamide, S55  
 gliclazide, S55  
 glimepiride, S55  
 glipizide, S55  
 glomerular filtration rate estimation, S73  
 GLP-1 receptor agonists, S50, S53, S54, S56, S58, S83  
 glucagon, S44  
 glucocorticoids, S101  
 glucose, S44. *see also* glycemic control  
 glyburide, S55, S83, S96  
 glycemic control  
   A1C (*see* A1C)  
   carbohydrate counting, S27  
   children, adolescents, S87, S89  
   continuous glucose monitoring (CGM), S39, S40, S101  
   hospital care, S100, S101  
   hyperglycemia, S9–S10, S42, S45, S96, S99–S101  
   hypoglycemia (*see* hypoglycemia)
- intercurrent illness, S45  
 kidney disease treatment, S73–S74  
 neurocognitive function, S82  
 neuropathy treatment, S77  
 older adults, S82, S83  
 omega-3 fatty acids, S27  
 physical activity in, S28  
 pregnancy, S95  
 recommendations, S39, S43, S44  
 self-monitoring of blood glucose (SMBG), S39–S40  
 targets, S43–S44  
 GRADE study, S54  
 grading system, S1–S2
- health care access, S8–S9  
 health disparities, S8  
 hearing impairment, S31  
 heart failure, S68  
 hemoglobinopathies, S14  
 hepatitis B, S30  
 herbal supplements, S26  
 HITECH Act, S99–S100  
 HIV patients, diabetes care in, S10  
 homelessness, S9  
 hospital care  
   admission considerations, S100  
   antihyperglycemic therapies, S100–S101  
   bedside glucose monitoring, S103  
   CGM, S39, S40, S101  
   computerized physician order entry, S99–S100  
   critical care setting, S100  
   diabetes self-management, S102  
   diabetic ketoacidosis (DKA), S13, S16–S17, S45, S58, S90, S101  
   discharge plan, S102–S103  
   enteral/parenteral feeding, S101  
   glucocorticoids, S101  
   glycemic control, S100, S101  
   hyperglycemia in, S100  
   hyperosmolar hyperglycemic state, S101  
   hypoglycemia, S99–S102  
   insulin therapy, S99, S100  
   medical nutrition therapy, S25–S27, S102  
   perioperative care, S101  
   recommendations, S99  
   target glucose ranges, S99–S101  
   type 1 diabetes, S100  
 HOT trial, S62  
 hydrochlorothiazide, S63  
 hyperglycemia, S9–S10, S42, S45, S96, S99–S101  
 Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, S18  
 hypertension, S60–S63, S81, S88–S89  
 hypertriglyceridemia, S65  
 hypoglycemia  
   in children, adolescents, S44, S87  
   glycemic control, S27, S28, S40  
   hospital care, S99–S102  
   maternal, S95  
   nutrition in control of, S27  
   in older adults, S82, S84  
   physical activity in control of, S28  
   predictors of, S102  
   prevention, S9, S27, S28, S101–S102  
   symptoms, S10
- treatment, S9, S44, S101–S102  
 type 1 diabetes, S44–S45  
 hypoglycemia unawareness, S44
- immune-mediated type 1 diabetes, S15  
 immunizations, S29–S30  
 IMPROVE-IT trial, S65  
 incident diabetes, statin use and, S66  
 incretin-based therapies, S53  
 indapamide–perindopril, S62–S63  
 infections, S79  
 influenza, S29  
 insulin, insulin secretagogues  
   basal, S40, S54, S57–S58  
   bolus, S58  
   carbohydrate counting, S27  
   characterization, S56  
   in children, adolescents, S90  
   continuous subcutaneous infusion, S58  
   CVD targeting, S43  
   hospital care, S99, S100  
   hypoglycemia unawareness, S44  
   inhaled, S58  
   neurocognitive function, S82  
   older adults, S83  
   oral agents, S40, S57–S58  
   physical activity, S28  
   physiology in pregnancy, S95, S96  
   self-monitoring of blood glucose (SMBG), S39–S40  
   type 1 diabetes, S52–S53  
 insurance, S9  
 islet cell transplantation, S53
- Japanese Americans, S17
- Kumamoto Study, S42
- laser photocoagulation therapy, S75, S76  
 LDL cholesterol, S64, S65, S68  
 lifestyle modification, S7, S36–S37, S47, S48, S62–S64, S68  
 linagliptin, S53–S55  
 lipase inhibitors, S37, S50  
 lipid management, S63–S66. *see also* fats  
 lipid profiles, S65  
 liraglutide, S50, S53, S54, S56, S58  
 liraglutide (Saxenda), S50  
 literacy deficiencies, S9  
 lixisenatide, S50, S53, S54, S56, S58  
 Look AHEAD, S47, S68  
 lorcaserin (Belviq), S50  
 loss of protective sensation, S78  
 lovastatin, S64
- macular edema, S75, S76  
 MAO inhibitors, S49  
 maturity-onset diabetes of the young (MODY), S13, S19–S20  
 medical evaluation, S31  
 medical nutrition therapy, S25–S27, S102. *see also* nutrition  
 Medicare, S8, S25  
 medications, S10, S17, S49, S103. *see also under specific conditions*  
 Mediterranean diet, S10, S27, S37  
 meglitinides, S54, S55  
 mental illness, S10  
 metformin  
   cardiovascular disease, S67, S68  
   children, adolescents, S90

- effectiveness of, S36, S37  
 hospital care, S101  
 older adults, S83  
 in pregnancy, S96  
 therapy generally, S53–S55
- metoclopramide, S77  
 miglitol, S55  
 mineralocorticoid receptor blockers, S74  
 Modification of Diet in Renal Disease (MDRD) study, S73
- naltrexone/bupropion (Contrave), S50  
 nateglinide, S54, S55  
 neonatal diabetes, S19  
 nephrologist, referrals to, S74  
 nephropathy, S27, S29, S72–S74, S89–S90  
 neuropathy, S28–S29, S76–S78, S90  
 NHANES, S7, S14, S31  
 niacin/statin therapy, S65–S66  
 NICE-SUGAR study, S100  
 nonketotic hyperosmolar state, S45  
 nucleoside reverse transcriptase inhibitors (NRTIs), S10  
 numeracy deficiencies, S9  
 nutrition  
   alcohol, S26, S65  
   carbohydrates, S27, S37  
   cognitive dysfunction and, S10  
   in diabetes prevention, S37  
   eating patterns, S26  
   energy balance, S26  
   fats, S26, S27  
   herbal supplements, S26  
   kidney disease treatment, S73  
   macronutrient distribution, S26  
   micronutrients, S26  
   older adults, S84  
   protein, S26, S27  
   sodium, S26, S27
- obesity  
   assessment, S47  
   bariatric surgery, S49–S51, S58  
   concomitant medications, S49  
   diet, S48 (*see also* nutrition)  
   lifestyle modification, S7, S36–S37, S47, S48, S62–S64, S68  
   pharmacotherapy, S48–S50  
   physical activity, S27–S29, S37, S48  
   recommendations, S48  
   treatment, S47, S48  
   weight management, S25–S27, S68
- obstructive sleep apnea, S31  
 olanzapine, S49  
 older adults  
   end-of-life treatment, S82–S85  
   geriatric syndromes screening, S81  
   hypertension, S81  
   hypoglycemia, S82, S84  
   long-term care facilities, S81, S84  
   neurocognitive function, S82  
   nutrition, S84  
   overview, S81–S82  
   palliative care, S60–S63, S81  
   pharmacological therapy, S83–S84  
   recommendations, S81  
   treatment, S82–S83
- omega-3 fatty acids, S27  
 ophthalmologist, referrals to, S75  
 opioid antagonist/aminoketone antidepressant combination, S50  
 orlistat, S37, S50  
 orthostatic hypotension, S77
- pancreatic transplantation, S53  
 Patient-Centered Medical Home, S7  
 PCSK9 inhibitors, S65  
 percent of days covered (PDC), S8  
 perindopril–indapamide, S62–S63  
 periodontal disease, S31  
 peripheral arterial disease (PAD), S78  
 peripheral neuropathy, S28–S29, S76–S78  
 phentermine/topiramate combination, S50  
 photocoagulation therapy, S75  
 physical activity, S27–S29, S37, S48  
 pioglitazone, S37, S54, S55  
 pitavastatin, S64  
 plasma glucose criteria, S13  
 pneumococcal pneumonia, S29–S30  
 pneumococcal polysaccharide vaccine 23 (PPSV23), S29–S30  
 POC meters, S103  
 position statements, S1  
 pramlintide, S53, S56  
 pravastatin, S64  
 prediabetes, S14–S17, S36  
 pregabalin, S77  
 pregestational diabetes, S94–S96  
 pregnancy  
   A1C levels, S95  
   antihypertensive medications in, S63, S97  
   blood pressure targets, S61  
   contraception, S97  
   gestational diabetes mellitus, S18–S20, S37, S94–S97  
   glucose monitoring, S95  
   glycemic control, S95  
   hyperglycemia, S96  
   insulin physiology, S95, S96  
   lactation, S96–S97  
   pharmacological therapy, S96, S97  
   postpartum care, S96–S97  
   preconception counseling, testing, S95  
   pregestational diabetes, S94–S96  
   recommendations, S94  
   retinopathy, S75–S76  
   type 1 diabetes, S96–S97  
   type 2 diabetes, S96–S97
- Professional Practice Committee, S3, S107–S108  
 proliferative diabetic retinopathy, S75, S76  
 protease inhibitors, S10  
 protein, S26, S27  
 psychosocial issues, S30, S87  
 P2Y<sub>12</sub> receptor antagonists, S67
- red blood cell turnover test, S14  
 referrals, S24, S30, S74, S75  
 reimbursement, DSME/DSMS, S25  
 renal function assessment, S72–S73  
 repaglinide, S54, S55  
 resistance training, S27  
 retinal photography, S75  
 retinopathy, S28, S73–S76, S90  
 revisions summary, S4–S5  
 Reye syndrome, S67  
 risperidone, S49  
 rosiglitazone, S37, S54, S55  
 rosuvastatin, S64
- SAVOR-TIMI 53 trial, S68  
 saxagliptin, S53–S55, S68  
 Saxenda (liraglutide), S50  
 schizoaffective disorder, S10  
 schizophrenia, S10  
 school, child care, S86–S87, S105
- scientific evidence grading, S1–S2  
 scientific statements, S1  
 SEARCH study, S89  
 self-monitoring of blood glucose (SMBG), S39–S40  
 sex differences, S8, S66–S67  
 SGLT2 inhibitors, S53, S54, S56, S58, S83  
 simvastatin, S64  
 sitagliptin, S53–S55, S68  
 smoking cessation, S29, S89  
 socioeconomic differences, S8  
 sodium, S26, S27  
 spironolactone, S74  
 SPRINT trial, S61–S62  
 SSRIs, S49  
 Standards of Care, S1  
 statins  
   in CHD management, S68  
   children, adolescents, S89  
   cognitive function and, S66  
   dementia and, S10  
   in lipid management, S64–S66  
   type 1 diabetes, S64–S65  
   type 2 diabetes, S63–S66
- sulfonylureas, S54, S55, S58, S83, S96, S101  
 sympathomimetic amine anorectic/antiepileptic combination, S50  
 systolic blood pressure, S62
- tapentadol, S77  
 TECOS trial, S68  
 testosterone levels, S31  
 thiazolidinediones, S37, S54, S55, S67, S83  
 thyroid disease, S88  
 tobacco, S29, S89  
 TODAY study, S90  
 tramadol, S77  
 Translating Research Into Action for Diabetes (TRIAD) study, S8  
 treatment. *see also specific therapies*  
   adherence, S8  
   DSME, DSMS, S7, S8–S9, S24–S25  
   exercise, S27–S29, S37, S48  
   foundations of care, S23  
   glucose, S44  
   hypoglycemia, S44  
   immunizations, S29–S30  
   initial care basis, S23–S24  
   intensification, S8  
   lifestyle modification, S7, S36–S37, S47, S48, S62–S64, S68  
   medical nutrition therapy, S25–S27, S102  
   ongoing care, S24  
   patient engagement, S23  
   pharmacological, S36, S37  
   psychosocial issues, S30  
   referrals, S24  
   smoking cessation, S29, S89  
   tailoring, S8–S9  
   technology in, S37  
   type 1 diabetes, S52–S53  
   type 2 diabetes, S53–S58  
   weight management, S25–S27, S68
- tricyclic antidepressants, S49, S77  
 2-hour plasma glucose, S13, S14  
 type 1 diabetes  
   A1C microvascular complications, S42  
   carbohydrate counting, S27  
   in children, adolescents, S86–S90  
   classification, S13  
   CVD outcomes and, S42  
   demographics, S6

- diagnosis, S15–S16
- differential diagnosis, S18
- epidemiology, S8
- glycemic control, S39
- hospital care, S100
- hypoglycemia, S9, S44–S45
- idiopathic, S15–S16
- immune-mediated, S15
- pharmacological therapy, S52–S53
- physical activity, S27–S29
- pregnancy, S96–S97
- retinopathy, S75
- risk factors, S16
- statin therapy, S64–S65
- type 2 diabetes
  - A1C microvascular complications, S42
  - bariatric surgery, S49–S51, S58
  - BMI, ethnicity factors, S17
  - carbohydrate counting, S27
  - children, adolescents, S18, S19
  - in children, adolescents, S90–S91
  - classification, S13
  - combination therapy, S53–S57
  - CVD outcomes and, S42–S43
  - demographics, S6, S8
  - diagnosis, S16–S19
  - differential diagnosis, S18, S19
  - exercise, S27–S29
  - glycemic control, S40
  - hyperglycemia in, S9–S10
  - hypoglycemia, S9
  - hypoglycemia in, S10
  - mental illness in, S10
  - obesity in, S48
  - pharmacological therapy, S53–S58
  - pregnancy, S96–S97
  - prevention, delay, S36–S37
  - resistance training, S27
  - retinopathy, S75
  - risk factors, S17
  - statin therapy, S63–S66
- UK Prospective Diabetes Study (UKPDS), S42, S67, S74
- venlafaxine, S77
- Veterans Affairs Diabetes Trial (VADT), S42–S43
- vildagliptin, S53–S55
- weight management, S25–S27, S68